MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329479 | Name: Nicotinamide Riboside Chloride
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nicotinamide riboside, also known as NR and SRT647, is a pyridine-nucleoside form of vitamin B3 that functions as a precursor to nicotinamide adenine dinucleotide or NAD+. NR blocks degeneration of surgically severed dorsal root ganglion neurons ex vivo and protects against noise-induced hearing loss in living mice. Nicotinamide riboside prevents muscle, neural and melanocyte stem cell senescence. Increased muscular regeneration in mice has been observed after treatment with nicotinamide riboside, leading to speculation that it might improve regeneration of organs such as the liver, kidney, and heart. Nicotinamide riboside also lowers blood glucose and fatty liver in prediabetic and type 2 diabetic models while preventing the development of diabetic peripheral neuropathy. Note: Nicotinamide Riboside chloride is a α/β mixture

Chemical Structure

Nicotinamide Riboside Chloride
CAS#23111-00-4 (chloride)

Theoretical Analysis

MedKoo Cat#: 329479

Name: Nicotinamide Riboside Chloride

CAS#: 23111-00-4 (chloride)

Chemical Formula: C11H15ClN2O5

Exact Mass: 0.0000

Molecular Weight: 290.70

Elemental Analysis: C, 45.45; H, 5.20; Cl, 12.19; N, 9.64; O, 27.52

Price and Availability

Size Price Availability Quantity
1g USD 150.00 Ready to ship
5g USD 350.00 Ready to ship
10g USD 450.00 Ready to ship
20g USD 750.00 Ready to ship
100g USD 1,850.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1341-23-7 (cation) 23111-00-4 (chloride) 445489-49-6 (Triflate)
Synonym
Nicotinamide riboside; SRT647; SRT-647; SRT 647; Nicotinamide Riboside Triflate, α/β mixture; NR Chloride
IUPAC/Chemical Name
3-carbamoyl-1-((3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium chloride
InChi Key
YABIFCKURFRPPO-FSDYPCQHSA-N
InChi Code
InChI=1S/C11H14N2O5.ClH/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11;/h1-4,7-9,11,14-16H,5H2,(H-,12,17);1H/t7-,8-,9-,11?;/m1./s1
SMILES Code
OC[C@@H]1[C@@H](O)[C@@H](O)C([N+]2=CC=CC(C(N)=O)=C2)O1.[Cl-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis, α/β mixture)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in water (10mg/mL)
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in water
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
High dose nicotinic acid is used as an agent that elevates high-density lipoprotein cholesterol, lowers low-density lipoprotein cholesterol and lower free fatty acids through a mechanism that is not completely understood. It was suggested that nicotinamide riboside might possess such an activity by elevating NAD in the cells responsible for reverse cholesterol transport. The discovery that the Wallerian degeneration slow gene encodes a protein fusion with NMN adenylyltransferase 1 indicated that increased NAD+ precursor supplementation might oppose neurodegenerative processes. ChromaDex acquired intellectual property on uses and synthesis of NR from Dartmouth College, Cornell University, and Washington University and began distributing NR as Niagen in 2013. In November 2015 ChromaDex received New Dietary Ingredient (NDI) status for Niagen from the U.S. Food and Drug Administration (FDA) and the FDA issued a generally recognized as safe (GRAS) No Objection Letter for Nicotinamide Riboside Chloride (NR) on August 3, 2016.
Biological target:
NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3.
In vitro activity:
To determine the metabolic fate of the NF in blood, an in vitro study was conducted in which equal amounts of 13C‐ and deuterium‐labelled nicotinamide riboside chloride were added to water, heparinised whole blood, heparinised plasma, and serum at a concentration of 39 μM. The nicotinamide riboside and NAM contents of the samples were analysed immediately (T0) or after incubation at 37°C for 5 and 10 min. Compared to T0, there was no significant change in the amount of nicotinamide riboside or NAM in water, plasma, and serum samples over the course of the 10 min incubation period. In contrast, the amount of nicotinamide riboside in whole blood decreased within 5 min, while the amount of NAM increased. Similar results were obtained when the samples were incubated at 4°C, although the kinetics of the decrease in the amount of nicotinamide riboside and increase in the amount of NAM in whole blood were delayed compared to those observed at 37°C. Similar results have been reported by Liu et al. The Panel notes that these results indicate that the NF can be metabolised to NAM in a cellular component of whole blood. Reference: EFSA J. 2019 Aug; 17(8): e05775. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7009190/
In vivo activity:
Exposure to degeneration-inducing levels of light suppressed retinal NAD+ levels. Mice undergoing light-induced retinal degeneration exhibited significantly suppressed retinal function, severely disrupted photoreceptor cell layers, and increased apoptosis and inflammation in the outer retina. Treatment with NR increased levels of NAD+ in retina and prevented these deleterious outcomes. This study is the first to report the protective effects of NR treatment in a mouse model of retinal degeneration. The positive outcomes, coupled with human tolerance to NR dosing, suggest that maintaining retinal NAD+ via systemic NR treatment should be further explored for clinical relevance. Reference: Invest Ophthalmol Vis Sci. 2020 Aug; 61(10): 47. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452859/
Solvent mg/mL mM comments
Solubility
Water 58.0 199.50
DMSO 50.0 172.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 290.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
EFSA Panel on Nutrition, Novel foods and Food allergens (NDA), Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Kearney J, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Engel KH, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Pöting A, Poulsen M, Sanz Y, Schlatter JR, van Loveren Agnès de Sesmaisons-Lecarré H, Germini A, Knutsen HK. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA J. 2019 Aug 7;17(8):e05775. doi: 10.2903/j.efsa.2019.5775. PMID: 32626405; PMCID: PMC7009190.
In vitro protocol:
1. EFSA Panel on Nutrition, Novel foods and Food allergens (NDA), Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Kearney J, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Engel KH, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Pöting A, Poulsen M, Sanz Y, Schlatter JR, van Loveren Agnès de Sesmaisons-Lecarré H, Germini A, Knutsen HK. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA J. 2019 Aug 7;17(8):e05775. doi: 10.2903/j.efsa.2019.5775. PMID: 32626405; PMCID: PMC7009190.
In vivo protocol:
1. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019 Jul 5;9(1):9772. doi: 10.1038/s41598-019-46120-z. PMID: 31278280; PMCID: PMC6611812. 2. Zhang X, Henneman NF, Girardot PE, Sellers JT, Chrenek MA, Li Y, Wang J, Brenner C, Nickerson JM, Boatright JH. Systemic Treatment With Nicotinamide Riboside Is Protective in a Mouse Model of Light-Induced Retinal Degeneration. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):47. doi: 10.1167/iovs.61.10.47. PMID: 32852543; PMCID: PMC7452859.
1: Suchard MS, Savulescu DM. Nicotinamide pathways as the root cause of sepsis - an evolutionary perspective on macrophage energetic shifts. FEBS J. 2021 Mar 8. doi: 10.1111/febs.15807. Epub ahead of print. PMID: 33686748. 2: Hussain M, Krishnamurthy S, Patel J, Kim E, Baptiste BA, Croteau DL, Bohr VA. Skin Abnormalities in Disorders with DNA Repair Defects, Premature Aging, and Mitochondrial Dysfunction. J Invest Dermatol. 2021 Apr;141(4S):968-975. doi: 10.1016/j.jid.2020.10.019. Epub 2021 Jan 19. PMID: 33353663; PMCID: PMC7987691. 3: Tannous C, Booz GW, Altara R, Muhieddine DH, Mericskay M, Refaat MM, Zouein FA. Nicotinamide adenine dinucleotide: Biosynthesis, consumption and therapeutic role in cardiac diseases. Acta Physiol (Oxf). 2021 Mar;231(3):e13551. doi: 10.1111/apha.13551. Epub 2020 Sep 21. PMID: 32853469. 4: English J, Son JM, Cardamone MD, Lee C, Perissi V. Decoding the rosetta stone of mitonuclear communication. Pharmacol Res. 2020 Nov;161:105161. doi: 10.1016/j.phrs.2020.105161. Epub 2020 Aug 23. PMID: 32846213; PMCID: PMC7755734. 5: Kang BE, Choi JY, Stein S, Ryu D. Implications of NAD+ boosters in translational medicine. Eur J Clin Invest. 2020 Oct;50(10):e13334. doi: 10.1111/eci.13334. Epub 2020 Jul 22. PMID: 32594513. 6: Morris G, Walder KR, Berk M, Marx W, Walker AJ, Maes M, Puri BK. The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it? Mol Biol Rep. 2020 Jul;47(7):5587-5620. doi: 10.1007/s11033-020-05590-5. Epub 2020 Jun 20. PMID: 32564227. 7: Bock KW. Aryl hydrocarbon receptor (AHR) functions: Balancing opposing processes including inflammatory reactions. Biochem Pharmacol. 2020 Aug;178:114093. doi: 10.1016/j.bcp.2020.114093. Epub 2020 Jun 11. PMID: 32535108. 8: Mehmel M, Jovanović N, Spitz U. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Nutrients. 2020 May 31;12(6):1616. doi: 10.3390/nu12061616. PMID: 32486488; PMCID: PMC7352172. 9: Galli U, Colombo G, Travelli C, Tron GC, Genazzani AA, Grolla AA. Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy. Front Pharmacol. 2020 May 12;11:656. doi: 10.3389/fphar.2020.00656. PMID: 32477131; PMCID: PMC7235340. 10: Custodero C, Saini SK, Shin MJ, Jeon YK, Christou DD, McDermott MM, Leeuwenburgh C, Anton SD, Mankowski RT. Nicotinamide riboside-A missing piece in the puzzle of exercise therapy for older adults? Exp Gerontol. 2020 Aug;137:110972. doi: 10.1016/j.exger.2020.110972. Epub 2020 May 22. PMID: 32450270. 11: Ramos KS, Brundel BJJM. DNA Damage, an Innocent Bystander in Atrial Fibrillation and Other Cardiovascular Diseases? Front Cardiovasc Med. 2020 Apr 28;7:67. doi: 10.3389/fcvm.2020.00067. PMID: 32411727; PMCID: PMC7198718. 12: Orlandi I, Alberghina L, Vai M. Nicotinamide, Nicotinamide Riboside and Nicotinic Acid-Emerging Roles in Replicative and Chronological Aging in Yeast. Biomolecules. 2020 Apr 15;10(4):604. doi: 10.3390/biom10040604. PMID: 32326437; PMCID: PMC7226615. 13: Jacobson KA, Reitman ML. Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs. Cells. 2020 Apr 13;9(4):956. doi: 10.3390/cells9040956. PMID: 32295065; PMCID: PMC7226956. 14: Bock KW. Modulation of aryl hydrocarbon receptor (AHR) and the NAD+-consuming enzyme CD38: Searches of therapeutic options for nonalcoholic fatty liver disease (NAFLD). Biochem Pharmacol. 2020 May;175:113905. doi: 10.1016/j.bcp.2020.113905. Epub 2020 Mar 10. PMID: 32169417. 15: Carrera-Juliá S, Moreno ML, Barrios C, de la Rubia Ortí JE, Drehmer E. Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review. Front Physiol. 2020 Feb 6;11:63. doi: 10.3389/fphys.2020.00063. PMID: 32116773; PMCID: PMC7016185. 16: Gilmour BC, Gudmundsrud R, Frank J, Hov A, Lautrup S, Aman Y, Røsjø H, Brenner C, Ziegler M, Tysnes OB, Tzoulis C, Omland T, Søraas A, Holmøy T, Bergersen LH, Storm-Mathisen J, Nilsen H, Fang EF. Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing. Mech Ageing Dev. 2020 Mar;186:111208. doi: 10.1016/j.mad.2020.111208. Epub 2020 Jan 15. PMID: 31953124. 17: Islam P, Horwitz ME. Small-molecule nicotinamide for ex vivo expansion of umbilical cord blood. Exp Hematol. 2019 Dec;80:11-15. doi: 10.1016/j.exphem.2019.11.006. Epub 2019 Nov 28. PMID: 31786243. 18: Bock KW. Functions of aryl hydrocarbon receptor (AHR) and CD38 in NAD metabolism and nonalcoholic steatohepatitis (NASH). Biochem Pharmacol. 2019 Nov;169:113620. doi: 10.1016/j.bcp.2019.08.022. Epub 2019 Aug 26. PMID: 31465774. 19. EFSA Panel on Nutrition, Novel foods and Food allergens (NDA), Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Kearney J, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Engel KH, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Pöting A, Poulsen M, Sanz Y, Schlatter JR, van Loveren Agnès de Sesmaisons-Lecarré H, Germini A, Knutsen HK. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA J. 2019 Aug 7;17(8):e05775. doi: 10.2903/j.efsa.2019.5775. PMID: 32626405; PMCID: PMC7009190. 20. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019 Jul 5;9(1):9772. doi: 10.1038/s41598-019-46120-z. PMID: 31278280; PMCID: PMC6611812.
1. Pinkerton M, Ruetenik A, Bazylianska V, Nyvltova E, Barrientos A. Salvage NAD+ biosynthetic pathway enzymes moonlight as molecular chaperones to protect against proteotoxicity. Hum Mol Genet. 2021 May 17;30(8):672-686. doi: 10.1093/hmg/ddab080. PMID: 33749726. 2. A Kumar, S Iqbal, N Pentinmikko, M Broberg. Alanine Catabolism of Paneth Cells Maintains Intestinal Stem Cell Function During Dietary Restriction. Current Biology. 2021- https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3959329 3. Walvekar AS, Warmoes M, Cheung D, Sikora T, Seyedkatouli N, Gomez-Giro G, Perrone S, Dengler L, Unger F, Santos BFR, Gavotto F, Dong X, Becker-Kettern J, Kwon YJ, Jäger C, Schwamborn JC, Van Bergen NJ, Christodoulou J, Linster CL. Failure to repair damaged NAD(P)H blocks de novo serine synthesis in human cells. Cell Mol Biol Lett. 2025 Jan 9;30(1):3. doi: 10.1186/s11658-024-00681-8. PMID: 39789421; PMCID: PMC11715087.